Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT01161472
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Registration Number
- NCT01046162
Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Registration Number
- NCT01027689
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
- Conditions
- Alzheimer's DiseaseHuntington's Disease
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00975481
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2010-02-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 222
- Registration Number
- NCT00921063
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg
- Conditions
- Anxiety
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 30
- Registration Number
- NCT00913341
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg
- Conditions
- Anxiety
- Interventions
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 26
- Registration Number
- NCT00912145
Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT00878865
- Locations
- 🇫🇮
Orion Pharma phase I unit, Espoo, Finland
Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT00878514
- Locations
- 🇫🇮
Orion Pharma Phase I unit, Espoo, Finland
Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Registration Number
- NCT00877955
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.